MedTrace Logo

Study of Nab-Paclitaxel in High Risk Early Breast Cancer

NCT01690702 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2886

Last updated 2021-02-02

No results posted yet for this study

Summary

two-armed trial to compare E-nP-C against tailored dtEC-dtD in patients with high risk early breast cancer

Conditions

Interventions

DRUG

Epirubicin

DRUG

nab-Paclitaxel

DRUG

Cyclophosphamide

DRUG

Docetaxel

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • Amgen

    collaborator INDUSTRY

  • GBG Forschungs GmbH

    lead OTHER

Principal Investigators

  • Gunter von Minckwitz, Prof. · GBG Forschungs GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2018-09-30
Completion
2020-07-20

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01690702 on ClinicalTrials.gov